Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) is a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, with an emphasis on oral, once-daily, non-statin treatments for patients with elevated LDL-C who are at risk for cardiovascular disease. This news page aggregates company announcements, clinical updates, partnership developments, and financial disclosures related to Esperion and its products.
Investors and healthcare-focused readers can use this feed to follow Esperion’s progress with NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), including regulatory milestones, commercialization updates, and guideline-related developments. Recent company communications highlight inclusion of bempedoic acid in major cardiovascular guidelines, presentations of new analyses from the CLEAR Outcomes trial, and expansion of access through partners in Europe, Japan, Canada and other regions.
News items also cover Esperion’s pipeline activities, such as the nomination of ESP-2001, a highly specific allosteric ATP-citrate lyase inhibitor for primary sclerosing cholangitis, and broader ACLY-focused research efforts. Financial and corporate updates, including quarterly results, capital raises via public offerings, and executive appointments, are reported through press releases and Form 8-K filings and are reflected in this news stream.
By reviewing the ESPR news feed, readers can see how Esperion describes its Vision 2040 strategy, commercial execution in the U.S. statin-intolerant market, international launches with partners, and ongoing safety and indication communications for NEXLETOL and NEXLIZET. This page offers a centralized view of the company’s publicly released information over time.
Esperion (NASDAQ: ESPR) will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025 at 3:30 p.m. ET.
Investors can access a live webcast on Esperion's investor website; a replay will be available approximately two hours after the call and archived for about 90 days. Esperion is a commercial-stage biopharmaceutical company developing oral, once-daily, non-statin medicines for patients with elevated LDL-C, supported by the nearly 14,000-patient CLEAR Cardiovascular Outcomes Trial. The company is advancing next-generation ATP citrate lyase inhibitors (ACLYi) and pursuing commercial execution and international partnerships.
Esperion (NASDAQ: ESPR) said partner HLS Therapeutics received Health Canada approval to market NILEMDO (bempedoic acid) for the reduction of LDL-cholesterol in Canadians at risk of cardiovascular disease.
Commercial launch in Canada is expected in Q2 2026. The announcement is positioned as part of Esperion's global strategy to expand access to bempedoic acid products.
The release cites Government of Canada figures that about 2.6 million adults (one in 12 aged 20+) live with diagnosed heart disease and that heart disease is the second leading cause of death in Canada, with roughly 14 adults aged 20+ dying every hour from diagnosed heart disease.
Esperion (NASDAQ: ESPR) presented two post hoc analyses from CLEAR Outcomes at AHA Scientific Sessions 2025 (Nov 7-10). In ~8,200 patients receiving no background lipid‑lowering therapy, bempedoic acid monotherapy lowered LDL‑C by 20.6% at 6 months and reduced MACE‑4 by 14% versus placebo. A separate exploratory analysis reported a 42% lower risk of venous thromboembolism (VTE) with bempedoic acid (106 VTE events over 40.6 months); DVT risk -44% and PE risk -39% versus placebo. Safety profiles were reported as similar for total and serious adverse events; labeling warns about hyperuricemia and tendon rupture.
Esperion (NASDAQ: ESPR) announced that on November 4, 2025 it granted 77,650 restricted stock units (RSUs) to 23 new employees under its 2017 Inducement Equity Incentive Plan pursuant to NASDAQ Rule 5635(c)(4).
The RSUs vest 25% on the one-year anniversary of each recipient’s vesting commencement date and the remaining 75% in twelve equal quarterly installments thereafter, subject to continued employment. The awards are governed by the 2017 Inducement Equity Incentive Plan and individual RSU agreements.
Esperion is a commercial-stage biopharmaceutical company commercializing FDA-approved oral, once-daily non-statin medicines for patients with elevated LDL-C and references the nearly 14,000-patient CLEAR Cardiovascular Outcomes Trial.
Esperion (NASDAQ: ESPR) reported Q3 2025 total revenue of $87.3M, up 69% year‑over‑year, driven by U.S. prescription volume and expanded payer coverage. U.S. net product revenue was $40.7M, up 31% Y/Y. The company announced a settlement with ANDA filer Dr. Reddy’s and three other filers preventing generic marketing of NEXLETOL and NEXLIZET prior to April 2040. Bempedoic acid received a Class I, Level A recommendation in the 2025 ESC/EAS guidelines. Partner Otsuka received Japanese approval and favorable preliminary pricing for NEXLETOL, which will trigger material milestone payments upon final pricing.
Esperion ended Q3 with $92.4M cash, reported a Q3 net loss of $31.3M, reiterated 2025 operating expense guidance of $215M–$235M, and expects sustainable profitability beginning Q1 2026.
Esperion (NASDAQ: ESPR) announced the appointment of John Harlow as Chief Commercial Officer, effective November 17, 2025. He will report to President and CEO Sheldon Koenig and join the executive leadership team.
Harlow joins from Melinta Therapeutics, where he served as CCO and led a commercial platform and team of ~80 employees, helping drive roughly 85% revenue growth in 2024 vs 2020. He has prior commercial leadership roles at Baudax Bio, Recro Pharma, Endo, Shionogi USA, Pfizer, Alpharma, and Novartis, plus an MBA in Pharmaceutical Management and Marketing.
Esperion cited Harlow’s experience as central to expanding U.S. adoption and the global footprint for its therapies NEXLETOL and NEXLIZET.
Esperion (NASDAQ: ESPR) will present at the Jefferies Global Healthcare Conference – London on November 18, 2025 at 8:00 a.m. GMT (3:00 a.m. ET).
The presentation will be webcast live and accessible via the company investor website. A replay will be available approximately two hours after the call and will be archived on the company website for approximately 90 days. Esperion is a commercial-stage biopharmaceutical company developing oral, once-daily, non-statin medicines for patients with elevated LDL-C and is advancing next-generation ACLY inhibitor programs supported by prior CLEAR outcomes research.
Esperion (NASDAQ: ESPR) will host a virtual Key Opinion Leader event on Tuesday, November 11, 2025 at 2:00 p.m. ET to discuss clinical and real-world challenges of statin intolerance and impacts on patient outcomes. The event is led by LeAnne Bloedon, VP, Head of Clinical Development, and features experts including Fatima Rodriguez, MD, MPH, and Dharmesh S. Patel, MD.
The company highlighted that nearly 20% of patients discontinue statins within one year and emphasized dialogue on strategies—including bempedoic acid therapies. A live audio webcast and replay (available ~2 hours after the call) will be posted on the investor section of the Esperion website and archived for ~90 days.
Esperion (NASDAQ: ESPR) announced that two analyses from the CLEAR Outcomes trial were accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, November 7-10, 2025.
An oral presentation titled “Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events: a secondary analysis of the CLEAR Outcomes trial” is scheduled for November 9, 2025, 9:45–11:00 AM CST, presented by Carolina Pires Zingano, MD of Cleveland Clinic. A poster, “Effects of Bempedoic Acid on Venous Thromboembolism: a Post-Hoc Analysis of the CLEAR Outcomes trial”, will appear in the moderated digital poster session VM.MDP.07 on November 9, 2025, 11:50 AM–1:05 PM CST, presented by Bernardo Frison Spiazzi, MD of Cleveland Clinic.
Company leadership highlighted that CLEAR Outcomes continues to yield clinically relevant insights on statin intolerance and treatment options for patients with elevated LDL-C.
Esperion (NASDAQ: ESPR) will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025.
Management will host a live webcast at 8:00 a.m. ET to discuss results and business updates; a replay will be available about two hours after the call and archived on the company website for ~90 days.
Esperion is a commercial-stage biopharmaceutical company marketing the only FDA-approved oral, once-daily non-statin therapies for patients with elevated LDL-C, supported by the ~14,000-patient CLEAR cardiovascular outcomes trial. The company is advancing next-generation ATP citrate lyase inhibitor (ACLYi) programs and pursuing international partnerships and commercial expansion.